Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Inclusion Criteria: * Consecutive patients with a newly diagnosed, objectively confirmed: symptomatic or unsuspected, proximal lower-limb DVT or symptomatic PE or unsuspected PE in a segmental or more proximal pulmonary artery; * Any type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intracerebral metastasis and acute leukemia); * Signed and dated informed consent of the patient, available before the start of any specific trial procedure. Exclusion Criteria: * age \<18 years; * ECOG Performance Status III or IV; * life expectancy of less than 6 months; Related to anticoagulant treatment: * administration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization; * 3 or more doses of a vitamin K antagonist before randomization; * thrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode; * indication for anticoagulant treatment for a disease other than the index VTE episode; Related to bleeding risk: * thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy; * active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; * recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery * hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count \<75x10\^9/L or history of heparin induced thrombocytopenia; * creatinine clearance \< 30 ml /min based on the Cockcroft Gault equation; * acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range; * uncontrolled hypertension (systolic BP\> 180 mmHg or diastolic BP \> 100 mmHg despite antihypertensive treatment); * concomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein; Standard criteria: * bacterial endocarditis; * hypersensitivity to the active substance or to any of the excipients of study drug; * patients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system; * childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; * any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study.